License Agreements - Broad License Agreement - Additional Information (Details) - Broad Institute |
12 Months Ended | ||
|---|---|---|---|
|
Jun. 10, 2021
shares
|
Dec. 31, 2023
USD ($)
|
May 31, 2021
USD ($)
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success payment amount due | $ 0 | $ 15,000,000 | |
| Issuance of common stock for success payment liability, Shares | shares | 174,825 | ||
| Success Payments | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Agreement description | The Company is required to make success payments to Broad Institute during a period of time, or the Broad Success Payment Period, which has been determined to be the earliest of (1) the twelfth anniversary of the Broad License Agreement or (2) the third anniversary of the first date on which a licensed product receives regulatory approval in the United States. During the Broad Success Payment Period, the Company will perform a calculation of any amounts owed to Broad Institute on each rolling 90-day period, commencing one year after the Company’s IPO. | ||
| Other Payments | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Agreement description | The Company agreed to pay Broad Institute an annual license maintenance fee ranging from low-to-mid five figures to low six figures, depending on the particular calendar year. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Broad Institute related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $75.9 million in product development and regulatory approval milestones, or Broad Product Milestones. If the Company completes a change of control during the term of the Broad License Agreement, then certain of the milestone payments would be increased. To the extent there are commercial sales of a licensed product, the Company is required to pay low single digit royalties on net sales. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country. If the Company sublicenses its rights to develop or commercialize a licensed product under the Broad License Agreement to a third party and the Company receives non-royalty sublicense income, then Broad Institute is entitled to a percentage of such consideration, ranging from the high single digits to low double digits depending on the date in which such sublicense agreement is executed and the stage of development of the Company’s licensed products at such time. | ||
| Minimum | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success payments | $ 5,000,000 | ||
| Minimum | Series A Preferred Stock | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success Payments, valuation multiples | 5 | ||
| Maximum | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success payments | $ 105,000,000 | ||
| Additional success payment amount due | $ 90,000,000 | ||
| Maximum | Series A Preferred Stock | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Success Payments, valuation multiples | 40 | ||
| Maximum | Product Development and Regulatory Approval | |||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | |||
| Aggregate milestone amount | $ 75,900,000 |